| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |